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b-Cell Failure in Type 2 Diabetes: A Case of Asking Too
Much of Too Few?
Safia Costes,1 Ralf Langen,2 Tatyana Gurlo,1 Aleksey V. Matveyenko,1 and Peter C. Butler1
The islet in type 2 diabetes (T2DM) is characterized by a deficit in
b-cells, increased b-cell apoptosis, and extracellular amyloid
deposits derived from islet amyloid polypeptide (IAPP). In the
absence of longitudinal studies, it is unknown if the low b-cell
mass in T2DM precedes diabetes onset (is a risk factor for di-
abetes) or develops as a consequence of the disease process.
Although insulin resistance is a risk factor for T2DM, most indi-
viduals who are insulin resistant do not develop diabetes. By
inference, an increased b-cell workload results in T2DM in some
but not all individuals. We propose that the extent of the b-cell
mass that develops during childhood may underlie subsequent
successful or failed adaptation to insulin resistance in later life.
We propose that a low innate b-cell mass in the face of subse-
quent insulin resistance may expose b-cells to a burden of insulin
and IAPP biosynthetic demand that exceeds the cellular capacity
for protein folding and trafficking. If this threshold is crossed,
intracellular toxic IAPP membrane permeant oligomers (cylin-
drins) may form, compromising b-cell function and inducing
b-cell apoptosis. Diabetes 62:327–335, 2013
ISLET PATHOLOGY IN TYPE 2 DIABETES
In type 2 diabetes (T2DM), the islet is characterized by
a deficit in b-cells, increased b-cell apoptosis, and extra-
cellular amyloid deposits derived from IAPP (1,2). The
question has long been posed, is islet amyloid (Fig. 1) in
T2DM the blood or the bullet (3,4)? In the neurosciences,
the bullet hypothesis gained ascendancy under the moni-
ker of the amyloid hypothesis in relation to Alzheimer’s
disease (5). Arguably, the diabetes field was appropriately
more skeptical because evidence in favor of a direct toxic
effect of islet amyloid (6) was outnumbered by studies that
did not identify such toxicity (7,8). However recent prog-
ress has seen a convergence of ideas by those pursuing
insights into the possible link between protein misfolding
and cellular degeneration in the neurosciences and the
islet field. The emerging alternative but related toxic olig-
omer hypothesis can be summarized as follows.
Amyloid deposits occur as a consequence of misfolding
and mistrafficking of proteins with the propensity to form
amyloid deposits. These proteins may form a variety of
oligomers, the most toxic of which are those that form
relatively early and form in or interact with cellular
membranes (7,9). In contrast, if misfolded IAPP oligomers
organize into amyloid fibrils, these are generally less toxic
but also relatively inert and as such tend to accumulate in
the extracellular space where they may play a role as
a physical barrier and as such contribute to cellular dys-
function (4,10). In order to appreciate why some proteins
have the propensity to form oligomers and amyloid fibrils,
it is helpful to consider the physical interactions that these
proteins share in common.
PROTEIN MISFOLDING AND OLIGOMERIZATION
A common feature of amyloid proteins, including IAPP, is
the ability to misfold into highly polymorphic oligomeric
and fibrillar structures. In vitro experiments have shown
that oligomers appear early during the misfolding process,
whereas fibrils represent the end point of misfolding
(11,12). Although some oligomers are likely to be on
pathway to fibril formation, others are not (Fig. 2). IAPP
fibrils exhibit the classical cross-b structure typical for
amyloid fibrils (13), and structural models have been
obtained using a number of experimental methods (14–16).
Best understood structurally are IAPP fibrils with striated
ribbon and twisted morphology (17), for which detailed
three-dimensional structural information has been obtained
(Fig. 2) (14,15). In both cases, IAPP takes up two-stranded
structures. The main difference lies in how the two strands
are arranged with respect to each other (Fig. 2). In the
model from striated ribbon fibrils, the strands are ap-
proximately in the same plane, whereas the strands from
twisted fibrils are more staggered. As is typical for almost
all disease-related amyloid proteins (18), both IAPP fibril
types take up a parallel and in-register structure. In these
structures, the same residues from different molecules
stack on top of one another. This structure is stabilized
by the stacking of the same hydrophobic residues, which
is much more favorable than that of residues with like
charges (18). Oligomer formation is also facilitated by the
interaction of hydrophobic residues, but much less is
known about oligomer structures in general. This is likely
due to their often transient and polymorphic nature, which
makes it more difficult to study them using structural
methods (19). Nevertheless, it is clear that a large range of
oligomers of varying sizes and structures exist and that
they share the general property of cytotoxicity (19–21).
Different conformationally specific antibodies have been
used to recognize different oligomer types (20,22–24).
Remarkably, some of these antibodies can detect oligom-
ers from a wider range of amyloid proteins, including
IAPP. A11 is a conformationally specific antibody that
recognizes a subset of toxic oligomers from a wide range
of amyloid diseases (20). Although no direct structural
information is available for any disease-causing amyloid
oligomer, Eisenberg and colleagues (25) recently reported
a major advance. They were able to determine the crystal
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PERSPECTIVES IN DIABETES
structure of A11-positive oligomers derived from a short
aB-crystallin peptide fragment. As with amyloid oligomers
in general, oligomers of this short peptide fragment were
toxic. In the crystal structure, this peptide took on an
overall cylindrical shape with antiparallel strands, which
the authors termed cylindrin (Fig. 2). This study could
provide important insights into the structure of other A11-
positive oligomers.
Based on the existing structural information available
for IAPP fibrils and oligomers, it is clear that IAPP is
a typical amyloid protein, which likely exerts its toxicities
via the same mechanisms as other amyloid proteins. This
similarity also includes membrane interaction. Membranes
play an important dual role in the misfolding of amyloid
proteins. Membranes are not only disrupted by the toxic
action of misfolded oligomers, but they can also accelerate
oligomer and fibril formation by orders of magnitude (26).
In the case of IAPP, it was found that this acceleration is
mediated by an a-helical intermediate that forms in the
presence of negatively charged lipids (27–29). A lipid that
can potently activate this misfolding pathway is phosphati-
dyl serine, which is commonly found in the cytosolic leaflets
of cellular membranes. Thus, IAPP molecules that escape
the secretory pathway into the cytoplasmic space are likely
to rapidly misfold and disrupt membrane integrity in vivo.
DEFENSES AGAINST PROTEIN MISFOLDING AND
AGGREGATION
The workload of a typical b-cell in protein synthesis,
folding, sorting, processing, and then disposal by either
secretion or degradation is remarkable (Table 1). An av-
erage human b-cell synthesizes, folds, processes, and then
either secretes or degrades ;10,000 proinsulin molecules
per minute even in the basal nonfed state (30,31). In ad-
dition, each b-cell synthesizes, folds, processes, and then
either secretes or degrades ;1,000 pro-IAPP molecules
per minute (32).
IAPP is assembled in the endoplasmic reticulum (ER)
as prepro-IAPP, an 89–amino acid protein, and then
FIG. 1. A: Human islets from a nondiabetic subject and a subject with T2DM (upper panel) and from a wild-type (WT) and a human IAPP transgenic
(HIP) rat (lower panel) stained for insulin (brown). Deposits of amyloid derived from IAPP are indicated by a white arrowhead. Original mag-
nification: 340. B: Alignment of IAPP ortholog proteins. Amino acid alignment of IAPP protein sequences identified in Homo sapiens (human,
CAA39504), human mutant (S20G), Macaca mulatto (monkey, XP_001098290), Felis catus (cat, NP_001036803), Mus musculus (mouse,
NP_034621), and Rattus norvegicus (rat, NP_036718). Dots correspond to conserved residues with human IAPP sequence. Red letters correspond
to the amyloidogenic sequence. C: Sections of islets from human IAPP transgenic mice labeled for oligomers (A11) and IAPP (5 nm and 10 nm gold,
respectively). IAPP- and oligomer-labeled aggregates were found adjacent to mitochondria (M), and mitochondrial integrity appeared to be
compromised (black arrow points to the aggregates penetrating mitochondria). Original magnification: 3120,000. This figure originally appeared
in an article by Gurlo et al. (50).
FIG. 2. IAPP misfolding pathways. A: Schematic illustration of a step-
wise misfolding pathway of IAPP that generates toxic oligomers as well
as a range of different fibril types. Although the structure of IAPP
oligomers remains elusive, the crystal structure of an A11 antibody–
positive oligomer structure has recently been reported (25) and is
shown in panel B. C and D: The reported structures for fibrils with
striated ribbons and twisted morphologies. The bottom shows the
structure of single IAPP molecule (green). In case of the striated rib-
bon, the two strands are approximately in the same plane while the two
strands in the fibrils with twisted morphology are offset. Individual
stacks of monomers were built using MFIBRIL (http://chemsoft.hsc.usc
.edu:8080/MFIBRIL/) and colored green, brown, and blue. MFIBRIL was
then used to dock individual stacks together to better mimic the fibril
structure (blue and magenta). Note that contacts in the striated rib-
bons are made between same monomeric subunits, whereas contacts in
the twisted fibrils are more staggered by packing strands from one
monomer subunit against strands from a monomer three layers above.
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processed to its mature 37–amino acid form within the
secretory pathway (Fig. 3) (33). The microenvironment of
the ER favors appropriate folding and maturation of ER
proteins, avoiding protein aggregation (34,35). The rate of
synthesis and delivery of proinsulin and pro-IAPP into the
ER is adaptively constrained to the rate at which the ER
can successfully fold and export these proteins into the
secretory pathway by a feedback signaling system termed
the unfolded protein response (34,35). The microenviron-
ment and chaperones in b-cell secretory vesicles are also
protective against IAPP aggregation (36–43). Proteins that
fail the ER quality control system are removed from the ER
and degraded by endoplasmic reticulum-associated deg-
radation (ERAD), also known as the ubiquitin/proteasome
system (44). Misfolded proteins are translocated to the
cytosol and ubiquinated. Polyubiquinated proteins are then
deubiquitinated prior to passage through the proteasome
(45). If misfolded proteins form aggregates, they are
removed by macroautophagy (hereafter referred to as
autophagy) (46,47). An isolation double membrane forms
in the cytoplasm to surround such intracellular targets to
generate an autophagosome that then fuses with a lyso-
some in which the sequestered material is degraded by
hydrolytic enzymes (Fig. 3). The autophagy/lysosomal
pathway is required for survival and function of b-cells and
is adaptively increased under conditions of increased
b-cell protein synthesis, for example in obesity (48,49).
The autophagy/lysosomal pathway is particularly impor-
tant for protection of long-lived cells against accumulation
TABLE 1
Estimated number of insulin molecules secreted per minute by
a typical b-cell in a lean individual in the fasting state
A lean individual (70 kg) secretes 2 pmol/kg/min insulin
in fasting state
Insulin (mol/min) ;140 3 10212
Insulin (molecules/min)* ;84 3 1012
Insulin (molecules/min/b-cell)† ;10,500
Given that ;30% proinsulin fails quality control, that only a relatively
small amount of insulin synthesized is secreted, and that half the 24-h
cycle is in the fed state, the likely synthetic rate of proinsulin per
b-cell per minute is likely to be much higher in reality. The estima-
tions take into account the following: *;6 3 1023 molecules in one
mole. †;800 3 106 b-cells in an adult human.
FIG. 3. Secretory pathway and mechanisms of b-cell defense against protein misfolding. The major b-cell secretory proteins, insulin and IAPP, are
synthesized and folded in the ER and then processed within the secretory pathway (Golgi and secretory vesicles). Misfolded proteins are targeted
to the ER-associated degradation, also known as ubiquitin-proteasome system (UPS), that involves ubiquitination of the targeted proteins, their
deubiquitination by enzymes such as UCH-L1, and subsequent degradation by the proteasome. If the ubiquitin-proteasome system fails or if protein
aggregates form, an alternative pathway of protein clearance becomes available: the autophagy pathway in which membranes surround the ma-
terial to be degraded (ubiquitinated proteins and protein aggregates but also damaged organelles and aged vesicles) to form autophagosomes that
fuse with lysosomes to allow degradation of their content.
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of toxic amyloidogenic oligomers such as IAPP and
Alzheimer’s b-protein (49–51).
Given the extraordinary workload of a typical b-cell, the
high potency of human IAPP to form toxic oligomers, and
the long lifespan of b-cells in humans (52), it is a remark-
able tribute to the defenses against protein misfolding and
aggregation that even in the setting of the further in-
creased workload in obesity, most b-cells do not accu-
mulate sufficient toxic oligomers to compromise b-cell
function in most individuals.
DEFENSES AGAINST PROTEIN AGGREGATION
OVERCOME: THE THRESHOLD CONCEPT
In humans with T2DM, the formation of intracellular
oligomers and extracellular amyloid fibrils implies that the
mechanisms to prevent accumulation of misfolded pro-
teins are overcome (50). There is a threshold of IAPP ex-
pression that if exceeded leads to formation of IAPP
oligomers and the adverse consequences that accrue (53–
57). This threshold may be breached because the burden
of protein synthesis is increased to a level that exceeds the
capacity of a healthy b-cell to fold, process, and dispose of
the proteins (by secretion or degradation) and/or because
the threshold is decreased. Human IAPP transgenic rodent
models and transduced b-cells imply that both of these
contribute (53–57). Human IAPP transgenic mice and rats
develop diabetes in a transgene dose-response manner
(55), or if human IAPP expression is increased by drug- or
obesity-induced insulin resistance (56,57).
However once the threshold for successful protein syn-
thesis and disposal is overcome, the ubiquitin/proteasome
and autophagy/lysosomal systems for elimination of pro-
tein aggregates become defective, further compromising
the capacity for protecting the cell from formation of toxic
IAPP oligomers (vide infra) (49,58).
THRESHOLD FOR SUCCESSFUL PROTEIN FOLDING AND
DISPOSAL OVERCOME: A ROLE FOR b-CELL MASS
FORMED IN CHILDHOOD?
The most common risk factor for T2DM is obesity. With
increasing obesity (BMI), insulin resistance increases, re-
quiring increased expression of insulin and IAPP (59). To
appreciate the synthetic workload placed on b-cells in
an individual, it is necessary to consider not only the
overall insulin demand but also the number of b-cells
by which this demand is met in that individual. The num-
ber of b-cells in humans increases during early childhood
through the mechanism of b-cell replication and then
remains relatively constant through adult life once the
capacity for b-cell replication declines after early child-
hood (1,2,60). An underappreciated but potentially im-
portant characteristic of the period of b-cell mass
expansion during the postnatal period is the wide range of
b-cell mass that then accrues (Fig. 4). A wide variance in
pancreatic b-cell fractional area and/or mass has been
observed in adult humans, monkeys, pigs, and rodents
(1,60–64). This variance is likely due in part to the in-
trauterine environment (65) and in part to genetic variance
(vide infra) (66).
If we consider the interaction of obesity-induced insulin
resistance and the wide range of b-cell mass after post-
natal expansion, the increment in the protein synthetic
burden per b-cell increases much more steeply in those
with a low versus high number of b-cells (Fig. 5).
THRESHOLD FOR SUCCESSFUL PROTEIN FOLDING AND
DISPOSAL OVERCOME: A ROLE FOR ADOLESCENCE,
PREGNANCY, AND AGING?
Transient insulin resistance and therefore increased b-cell
workload occurs during adolescence in relation to high
levels of growth hormone and sex steroid secretion (67)
(Fig. 6). Obesity in adolescence superimposes additional
insulin resistance and b-cell workload. We propose that in
individuals with a low innate b-cell mass after childhood
(individual C, Figs. 4 and 6), the b-cell workload may ex-
ceed the threshold for protein folding so that toxic IAPP
FIG. 4. b-Cell mass growth varies widely in childhood. Postnatal ex-
pansion of b-cell number plays a major role in establishing b-cell mass
in adult humans and is highly variable between individuals. Data are
from Meier et al. (60). Total number of b-cells in 46 children aged 2
weeks to 21 years. Data are represented as individual data points.
Individuals with high (A, blue), intermediate (B, green), and low (C,
red) b-cell numbers are shown for consideration of b-cell workload in
response to obesity in Fig. 5.
FIG. 5. Interaction of postnatal b-cell mass and BMI on insulin and
IAPP synthetic demand. Schematic representation of the risk of T2DM
in individuals with high (A, blue), intermediate (B, green), and low (C,
red) b-cell mass formed after postnatal growth (see Fig. 4) with con-
sideration of their BMI. The increment in the protein synthetic burden
per b-cell increases more steeply in those with low (individual C) ver-
sus a high number of b-cells (individual A). The burden placed on
b-cells by obesity is thus higher in individual C, as is the risk to breach
the threshold for protein folding and disposal, ultimately leading to
b-cell failure in T2DM.
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oligomers may then form, leading to b-cell dysfunction
and, with time, b-cell loss and diabetes. A similar argument
can be made for the transient insulin resistance in the third
trimester of pregnancy leading to diabetes in some indi-
viduals. If the period of insulin resistance is rapidly re-
versed (as in delivery of the baby), then provided that
b-cell mass has not been sufficiently degraded, reversal of
diabetes may occur. Moreover, if the gestational diabetes
mellitus resolves, the risk for subsequent development of
T2DM depends on the b-cell workload in that individual
(68).
The incidence of T2DM increases with aging (69). In
most individuals, insulin sensitivity declines with aging
(70). There are also age-related changes in long-lived
cells, such as b-cells, that likely decrease the threshold
for successful protein synthesis, folding, and disposal.
Aged cells accumulate mitochondrial mutations leading
to increased production of reactive oxygen species (71).
The latter react with and damage proteins, placing an
increased burden on the pathways for clearance of dena-
tured proteins and damaged organelles (71). Furthermore,
the mechanisms that defend against accumulation of
misfolded or aggregated proteins in long-lived cells de-
cline with aging (72). There is decreased chaperone pro-
tein availability and decreased function of the ubiquitin/
proteasome system with aging (72). Acquired proteasome
abnormalities such as pesticide exposure contribute to
the pathogenesis of Parkinson’s disease, characterized by
synuclein aggregation (73). Given the parallels between
neurons in neurodegenerative diseases and islets in T2DM,
it would be of interest to determine if age-related changes
and environmental insults/pesticides inhibit proteasomal
function in b-cells and thus contribute to the pathogenesis
of T2DM.
The autophagy/lysosomal pathway also declines with
age (74). In liver of old rodents, fusion of autophagosomes
with lysosomes is impaired (75). Several age-related brain
diseases are also considered as disorders of lysosomal
function, and the mechanisms of neurodegeneration are
related to degradative failure and lysosomal destabilization
(76). Decreased clearance of b-amyloid was reported in late-
onset Alzheimer’s disease (77). The autophagy/lysosomal
pathway is impaired in b-cells in T2DM (78).
With the gradual increasing b-cell workload in a typical
individual, the vulnerability of b-cells in that individual to
cross the b-cell threshold for protein synthesis and folding
will depend on the b-cell mass present at the end of
childhood. Thus in individual A (Fig. 6), even in late life the
relatively high b-cell mass that arose in childhood is suf-
ficient. In individual B, with an intermediate b-cell mass,
the capacity for b-cell protein folding is only overcome in
late adult life with increasing insulin resistance. In con-
trast, in individual C, if he/she did not develop sustained
diabetes due to obesity in adolescence or with pregnan-
cies, diabetes onset is still likely at a young age. An im-
plication of this model for T2DM is that if b-cell workload
is maintained at relatively low levels by avoiding insulin
resistance, then T2DM can be avoided in most individuals.
LESSONS FROM GENETICS?
Genome-wide association studies (GWASs) have revealed
a variety of T2DM susceptibility genes (e.g., KCNJ11,
TCF7L2, CDKAL1) that are mainly involved in pancreatic
b-cell maturation and function (rev. in 79). Of interest,
several of these genes regulate the cell cycle and therefore
may play a role in the b-cell numbers that arise during the
period of postnatal expansion through b-cell replication
(such as CDKAL1 and CDC123 [80]). Among other iden-
tified genes, WFS1 (encoding Wolframin) has an essential
role in the ER unfolded-protein response and ER homeo-
stasis (81) and is involved in granule acidification in b-cells
(82). Any genetic alteration of WFS1, by its action to
compromise ER function and intravesicular pH, might be
expected to increase the risk of human IAPP misfolding
and oligomerization. T2DM is also associated with gene
variants associated with insulin-degrading enzyme. Insulin-
degrading enzyme degrades IAPP and inhibits IAPP aggre-
gation and toxicity in vitro (83). A rare missense mutation,
S20G, that leads to increased propensity of IAPP to form
oligomers is associated with T2DM, providing a proof of
principal of the potential importance of IAPP in the path-
ogenesis of diabetes (84,85).
Although insulin resistance is a well-known risk factor
for T2DM (86), GWASs have uncovered relatively few
FIG. 6. b-Cell workload and risk of T2DM. Schematic representation of
b-cell workload (in black) and b-cell work capacity (green) throughout
life. b-Cell workload increases transiently during adolescence and
progressively with aging. The capacity for b-cell workload is defined by
the b-cell mass after the postnatal expansion (high in individual A,
intermediate in individual B, and low in individual C, see Fig. 4) and
b-cell ability to defend against protein misfolding (declines in all indi-
viduals with aging). T2DM risk increases when workload exceeds ca-
pacity (light orange), in adolescence and early adult life in C, later in B,
and only with advanced age in A.
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associations with T2DM attributable to insulin-signaling
pathways. However the current model links insulin re-
sistance from any cause to T2DM risk through formation
of inadequate b-cell number in childhood and/or a reduced
capacity for protein folding, and both these mechanisms
are prominent in the GWASs to date.
WHERE DO OLIGOMERS FORM, AND HOW DO THEY
DAMAGE CELLS?
Amyloidogenic proteins such as IAPP appear to induce
cytoxicity by disrupting cellular membrane integrity in the
form of small nonfibrillar oligomers (7). Toxic IAPP
oligomers form within the secretory pathway but are then
found liberated from this compartment adjacent to dis-
rupted vesicle membranes (Fig. 1C) (50). Moreover,
membranes of mitochondria adjacent to these cytosolic
IAPP toxic oligomers are disrupted, implying that b-cell
function as well as viability is likely compromised by toxic
IAPP oligomers (Fig. 1). This is supported by the decline in
b-cell function that precedes loss of b-cell mass in the
human IAPP transgenic rat model of T2DM (64).
It is unclear where the toxic oligomers form within the
secretory pathway and even to what extent pro-IAPP has
been processed before these oligomers form. Since toxic
oligomers of amyloidogenic proteins form on an alterna-
tive pathway to the majority of amyloid fibrils, just because
IAPP-derived amyloid is primarily composed of the 37–
amino acid form of IAPP does not mean that the toxic
oligomers are. A case has been made that these toxic
oligomers might be composed of pro-IAPP (87). Pro-IAPP
oligomers could form in the ER and/or Golgi, whereas
IAPP oligomers would form in insulin secretory vesicles
where pro-IAPP processing to IAPP is completed.
Toxic oligomers associated with ER membranes (50)
may contribute to ER stress in b-cells of individuals with
T2DM (88). Human IAPP transgenic rodent models of
T2DM that form toxic IAPP oligomers have ER stress–
induced apoptosis (88,89). In those models, toxic oligom-
ers are found in association with the ER membrane, which
is likely the cause of unregulated ER Ca2+ release to the
cytosol and consequent hyperactivation of the Ca2+ sen-
sitive protease calpain-2 (53). The presence of this dele-
terious mechanism in humans was supported by the
detection of the cleaved form of a-spectrin, a marker of
calpain hyperactivation, in b-cells of individuals with
T2DM (53).
Once IAPP toxic oligomers are formed, they disrupt the
pathways of protein clearance and likely thereby lead to
further accumulation of protein aggregates. The ubiquitin/
proteasome system is dysfunctional in b-cells of human
individuals with T2DM, as demonstrated by the accumu-
lation of polyubiquitinated proteins (58). Increased ex-
pression of oligomerization-prone human IAPP leads to an
accumulation of polyubiquitinated proteins mediated by
a deficit in the deubiquitinating enzyme ubiquitin carboxyl-
terminal hydrolase L1 (UCH-L1) (58). UCH-L1 downreg-
ulation enhances ER stress–induced b-cell apoptosis, and
UCH-L1 deficiency was observed in b-cells of individuals
with T2DM (58). Therefore, defective protein degradation
in b-cells in T2DM can, at least in part, be attributed to
misfolded human IAPP leading to UCH-L1 deficiency,
which in turn further compromises b-cell viability by ex-
acerbating ER stress.
In summary, once the threshold for successful synthesis,
folding, processing, and secretion of IAPP is breached and
intracellular toxic oligomers begin to form, unless this is
rapidly reversed, a cascade of events occurs that further
compromises b-cell function and increases vulnerability to
b-cell apoptosis (Fig. 7). Moreover, the resulting declining
b-cell number adds an increased synthetic burden on the
remaining b-cells exacerbating the accumulation of toxic
oligomers.
EXTRACELLULAR ISLET AMYLOID AS A DIFFUSION
BARRIER?
Although accumulating data suggest that toxic IAPP
oligomers form intracellularly (50,55,90), and on a sepa-
rate pathway to the majority of fibrils present extracellu-
larly (25), this does not rule out a contributory role of
extracellular islet amyloid in b-cell dysfunction. It is not
known why extracellular islet amyloid forms in most islets
in T2DM and occasional islets in nondiabetic individuals.
The most obvious explanation is that it represents the
debris from cell apoptosis trapped on the vascular endo-
thelium where it appears to accumulate. Support for this is
provided by the absence of extracellular islet amyloid in in
vivo models of relatively rapid b-cell loss with high human
IAPP expression (55) but accumulation of extracellular
islet amyloid in more gradual-onset in vivo models (57,64).
However, islet amyloid develops rapidly in islets derived
from a human IAPP transgenic mouse in vitro. Also in this
model, it was reported that there was no evidence of ER
stress and that toxicity was attributed to extracellular islet
amyloid (91). It is difficult to interpret studies of b-cell
apoptosis in isolated islets in which there is already
a markedly increased frequency of b-cell apoptosis due to
anoxia and nutritional deprivation of the majority of cells.
In vivo, each b-cell is directly supplied by oxygen and
nutrients via an afferent vascular capillary loop, whereas
in isolated islets only cells at the out rim of the sphere of
;3,000 cells have direct nutrient and oxygen supply, the
remainder requiring diffusion through the sphere of cells
given the loss of a vascular supply. It is also therefore
perhaps not surprising that there is rapid accumulation of
extracellular IAPP-derived islet amyloid in vitro because
there is no means to export the secreted IAPP or IAPP
debris from apoptotic cells that accumulates between
cells. This rapidly accumulating amyloid between cells in
vitro presumably also acts as a diffusion barrier and, as
such, may contribute to b-cell apoptosis in islets in vitro.
The question arises, does the extracellular islet amyloid
in vivo contribute to b-cell dysfunction or apoptosis in
T2DM in the vascularized islet? We have found no re-
lationship between islet amyloid and b-cell apoptosis in
humans with T2DM (1) or transgenic human IAPP rodent
models (8). On the other hand, Jurgens et al. (92) report
an increase in a derivative of b-cell apoptosis (b-cell
apoptosis/insulin-positive area/islet area) related to a score
of islet amyloid in humans with T2DM and nondiabetic
individuals in the same analysis.
A more compelling case for an adverse effect of extracel-
lular islet amyloid can perhaps be made for transplanted
human islets. Extracellular islet amyloid also develops
rapidly in transplanted human islets (93), a circumstance
that more closely mirrors islets in vitro, since transplanted
islets take several days to reestablish a vascular supply
(94). During that period there is rapid loss of b-cells, pre-
sumably in part because of anoxia and nutrient deprivation
but perhaps exacerbated by the diffusion barrier of ex-
tracellular islet amyloid. A case can also be made that the
b-CELL FAILURE IN TYPE 2 DIABETES
332 DIABETES, VOL. 62, FEBRUARY 2013 diabetes.diabetesjournals.org
extracellular islet amyloid might compromise cell to cell
communication, known to be important for islet function.
It is unknown at present to what extent this might be rel-
evant in vivo.
CONCLUSION
Cross-sectional autopsy studies reveal a b-cell deficit and
increased b-cell apoptosis in T2DM. Though an increased
b-cell workload (insulin resistance) is a risk factor for
T2DM, most individuals adaptively increase insulin and
IAPP expression and secretion without b-cell failure. Ex-
perimental evidence supports the concept of a threshold of
synthetic burden in b-cells expressing amyloidogenic hu-
man IAPP beyond which accumulation of misfolded toxic
oligomers comprises b-cell function and viability. We
propose that the wide range of b-cell numbers between
individuals that becomes apparent after the period of
postnatal b-cell mass expansion may serve as an important
predictor of risk for T2DM. In those individuals with
a relatively low compliment of b-cells, insulin resistance
would markedly increase the already high burden for IAPP
and insulin folding and disposal (secretion or degradation)
per b-cell, potentially exceeding the threshold in at least
some b-cells. In those b-cells, the accumulating toxic
oligomers would compromise b-cell function and viability,
leading to a progressive loss of b-cell function and number.
As b-cell function declines in the presence of insulin re-
sistance, hyperglycemia that develops can initially be re-
versed by an increase in insulin sensitivity (for example,
delivery of child after gestational diabetes mellitus or in-
troduction of an exercise regimen [95]) but eventually
becomes irreversible if sufficient b-cell mass is lost. We
thus postulate that the innate b-cell mass that arises
according to intrauterine development and genetic im-
printing may be an important predictor of risk for T2DM in
the setting of insulin resistance. To rigorously test this
postulate it would be necessary to measure b-cell mass in
vivo in prospective studies of young adults over many
years.
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